OncoMatch/Clinical Trials/NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Is NCT05100862 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Zanubrutinib and Rituximab for relapsed/refractory follicular lymphoma.
Treatment: Zanubrutinib · Rituximab · Lenalidomide · Obinutuzumab — The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Cancer type
Non-Hodgkin Lymphoma
Prior therapy
Must have received: anti-CD20 agent
Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
Cannot have received: lenalidomide or drug from same class (lenalidomide)
Exception: if without response (partial or complete) or short remission duration (< 24 months)
Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (< 24 months)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ucsf Fresno University of California San Francisco Fresno · Fresno, California
- Kaiser Permanente Southern California · Irvine, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- Los Angeles Cancer Network · Los Angeles, California
- Valkyrie Clinical Trials · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05100862 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior lenalidomide or drug from same class disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages